Celcuity (CELC) Stock Forecast & Price Target

Celcuity is projected to have a positive financial outlook, with expected increases in product sales reaching $70/462/827M in FY26/27/28, driven by expedited regulatory timelines and early market share gains. This positive outlook is further supported by increased peak market share and sales estimates in both 2L PIK3CAwt/mt patient populations, and an increased likelihood of positive VIKTORIA-1/Study-2 data. Risks to this outlook include potential challenges in commercialization, regulation, and intellectual property. However, management is actively exploring ways to leverage the available data to expand eligibility for future studies, potentially including all-comer 1L HR+ MBC trials. The ongoing VIKTORIA-2 trial is expected to continue enrolling patients until mid-2026, with a focus on dosing in the safety lead-in and randomized portions, potentially expanding eligibility to endocrine sensitive patients and further narrowing the gap between Celcuity and Roche's triplets.

Celcuity is a clinical-stage biotechnology company with its lead therapeutic candidate, gedatolisib, showing potential in PIK3CA wild-type and mutant tumors. However, there are concerns about the company's financials as indicated by the loss on sale of fixed assets and expenses related to ongoing trials. There is also uncertainty around the company's commercial potential given competition in the targeted therapies market and a lack of clear differentiation of gedatolisib from other existing therapies. These factors, along with potential delays in clinical trial results, contribute to our negative outlook on Celcuity's stock.